Abstracts

IMMUNE STATUS AND SARS-CoV-2 VIRAL DYNAMICS

Background: Immunocompromised persons are disproportionately affected by severe SARS-CoV-2 infection, but immune compromise is heterogenous, which may impact viral dynamics. We hypothesized that higher degrees of compromised immunity are associated with higher viral shedding and slower viral clearance in the absence of COVID-19 therapeutics. Methods: Participants enrolled in ACTIV-2/A5401, a platform trial for COVID-19 therapeutics…

c-Myc AND NR4A REGULATE STOCHASTIC REACTIVATION OF LATENT HIV-1

Background: The “shock and kill” approach to eliminate HIV-1 latent reservoirs uses Latency Reversing Agents (LRA) to activate the provirus. At present reactivation in 100% of the latent cells is not possible and one reason is the stochasticity or ‘noise’ in pro-viral transcriptional activation. Current strategies do not address stochasticity in reactivation during LRA treatment.…

HIV-1 VIRAL RESERVOIR REACTIVATION AFTER CCR5 DELTA 32/32 STEM CELL TRANSPLANTATION

Background: To date, four persons living with HIV infection (PLWH) have achieved HIV cure through CCR5∆32 homozygous allogeneic stem cell transplantation (SCT). Post-SCT events leading to remission in this setting are uncertain, and no detailed analyses of HIV reactivation have been reported. Here we conducted virologic and immunologic analyses of HIV reactivation after CCR5∆32/∆32 SCT.…

A LOW-COST, RAPID URINE TEST FOR TFV INCREASES ART ADHERENCE AND VIRAL SUPPRESSION

Background: Innovative approaches are needed to achieve the third UNAIDS 95-95-95 target, to sustain virologic suppression (VS) in patients on ART. Tenofovir (TFV)-dolutegravir (DTG)-lamivudine (TLD) is first-line ART recommended by the World Health Organization (WHO). Virologic failure in patients on TLD is likely due to non-adherence because of DTG’s high barrier to resistance. Identifying non-adherence…

DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF MPOX WITHIN A NEW YORK CITY HEALTH SYSTEM

Background: Since the global mpox outbreak began in Spring 2022, it has disproportionately affected gay and bisexual individuals. Mpox can cause serious illness, including painful mucosal lesions, superinfections, and ocular disease. Its presentation in hospitalized patients and those with HIV/AIDS and other immunocompromising conditions is not yet well described, nor is the efficacy of therapies…